Comparison of ω-3 fatty acids and sulfasalazine in ulcerative colitis

Dichi, Isaías; Frenhane, Patrícia; Dichi, Jane Bandeira; Corrêa, Camila Renata; Angeleli, Aparecida Yooko Outa; Bicudo, M. H.; Rodrigues, Maria Aparecida Marchesan; Victória, Carlos Roberto; Burini, Roberto Carlos

doi:10.1016/s0899-9007(99)00231-2

Cited by 64 publications

(35 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Likewise there was a significant difference in the proportion of patients who remained in remission at 12 months: 59% in the fish oil group versus 26% in the placebo group (p = 0.003). Two studies not listed in Table 3 also merit discussion [98,99]. In a randomised, placebo-controlled trial, Middleton et al [98] gave patients with ulcerative colitis a preparation that included the n-6 PUFA GLA (1.62 g/day) in addition to EPA (0.27 g/day) and DHA (0.045 g/day) for 12 months.…”

Section: Trials Of N-3 Pufas In Inflammatory Bowel Diseasesmentioning

confidence: 99%

“…Middleton et al [98] found no differences in relapse rate or sigmoidoscope score between the placebo and PUFA groups. Dichi et al [99] randomised patients with ulcerative colitis to sulphasalazine (2 g/day) or fish oil (3.2 g EPA + 2.16 g DHA/day) for 2 months in a crossover design. Neither treatment changed colonic histology score from study entry; however, fish oil, but not sulphasalazine, significantly decreased the sigmoidoscope score [99].…”

Section: Trials Of N-3 Pufas In Inflammatory Bowel Diseasesmentioning

confidence: 99%

“…Dichi et al [99] randomised patients with ulcerative colitis to sulphasalazine (2 g/day) or fish oil (3.2 g EPA + 2.16 g DHA/day) for 2 months in a crossover design. Neither treatment changed colonic histology score from study entry; however, fish oil, but not sulphasalazine, significantly decreased the sigmoidoscope score [99]. Reviews of trials of fish oil in inflammatory bowel diseases have been published [105 -107] and these conclude that there is some benefit from fish oil in inflammatory bowel diseases.…”

Section: Trials Of N-3 Pufas In Inflammatory Bowel Diseasesmentioning

confidence: 99%

See 2 more Smart Citations

Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases

Calder

2008

Molecular Nutrition Food Res

391

305

View full text Add to dashboard Cite

With regard to inflammatory processes, the main fatty acids of interest are the n-6 PUFA arachidonic acid (AA), which is the precursor of inflammatory eicosanoids like prostaglandin E(2) and leukotriene B(4), and the n-3 PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). EPA and DHA are found in oily fish and fish oils. EPA and DHA inhibit AA metabolism to inflammatory eicosanoids. They also give rise to mediators that are less inflammatory than those produced from AA or that are anti-inflammatory. In addition to modifying the lipid mediator profile, n-3 PUFAs exert effects on other aspects of inflammation like leukocyte chemotaxis and inflammatory cytokine production. Some of these effects are likely due to changes in gene expression, as a result of altered transcription factor activity. Fish oil has been shown to decrease colonic damage and inflammation, weight loss and mortality in animal models of colitis. Fish oil supplementation in patients with inflammatory bowel diseases results in n-3 PUFA incorporation into gut mucosal tissue and modification of inflammatory mediator profiles. Clinical outcomes have been variably affected by fish oil, although some trials report improved gut histology, decreased disease activity, use of corticosteroids and relapse.

show abstract

Section: Trials Of N-3 Pufas In Inflammatory Bowel Diseasesmentioning

confidence: 99%

Section: Trials Of N-3 Pufas In Inflammatory Bowel Diseasesmentioning

confidence: 99%

Section: Trials Of N-3 Pufas In Inflammatory Bowel Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases

Calder

2008

Molecular Nutrition Food Res

391

305

View full text Add to dashboard Cite

show abstract

“…Another random double-blind placebo crossover study showed that PUFA improved the oxidative stress status in active UC patients receiving sulfasalazine [77] . Another small study showed that PUFA have some efficacy against UC, but it is less than that of sulfasalazine [78] . Thus, the efficacy of PUFA or fish oil against CD or UC is, at best, marginal; however, none of the studies reported any adverse effects of PUFA supplementation.…”

Section: Polyunsaturated Fatty Acids or Fish Oil Supplementsmentioning

confidence: 99%

Antioxidant Supplements and Gastrointestinal Diseases: A Critical Appraisal

2017

View full text Add to dashboard Cite

The gastrointestinal tract digests and absorbs dietary nutrients, protects the body against physical and chemical damage from contents in its lumen, provides immunity against external antigens, and keeps an optimum environment for the gut microbiota. These functions cannot be performed normally in several diseases of which the following are discussed here: irritable bowel syndrome and inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis. Because these diseases are associated with oxidative stress, a host of antioxidant supplements are used for maintenance and recovery of the gut functions. However, the benefits of these supplements have not been established. The available 80 human trials were rated for levels of confidence and for benefits of the antioxidant supplements. For Crohn's disease, the supplements for which clear benefits occurred in at least 2 studies were allopurinol, Boswellia serrata (frankincense or shallaki), Artemesia species (wormwood), Tripterygium wilfordii (léi gōng téng), and omega-3 fatty acids. Similar beneficial supplements for ulcerative colitis were allopurinol, Matricaria chamomilla (chamomile), Curcuma longa (curcumin in turmeric), and omega-3 fatty acids. There was also a clear benefit for ulcerative colitis in 2 studies where a multiherbal Chinese medicine preparation and an Ayurvedic medicine preparation were used. For irritable bowel syndrome, there was only a marginal benefit of some of the antioxidant supplements. Thus, some antioxidant supplements may be beneficial at certain stages of specific diseases. This is consistent with the current concept that antioxidants act by inhibiting oxidative stress pathways in a tissue- and environment-specific manner and not by simply acting as scavengers.

show abstract

“…Among these, IEF that includes immunonutrients such as arginine [35], glutamine [36,37], n-3 fatty acids [38,39], and nucleic acids [40,41] is commercially available to reduce the incidence of infectious complications after surgical insults [42][43][44]. Immunonutrition is appealing as a novel approach to favorably modulate the immunodysfunction associated with surgical insults.…”

Section: Enteral Formula Used For Early Enteral Nutrition After Esophmentioning

confidence: 99%

Is postoperative early enteral nutrition with regular or disease-specific enteral formula really beneficial in patients undergoing esophagectomy?

et al. 2009

View full text Add to dashboard Cite

Comparison of ω-3 fatty acids and sulfasalazine in ulcerative colitis

Cited by 64 publications

References 22 publications

Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases

Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases

Antioxidant Supplements and Gastrointestinal Diseases: A Critical Appraisal

Is postoperative early enteral nutrition with regular or disease-specific enteral formula really beneficial in patients undergoing esophagectomy?

Contact Info

Product

Resources

About